Loading…
Medicare Home Infusion Site of Care Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (32)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2018 · second_quarter · Medicare/Medicaid
114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act HR 3178, S. 1738, HR 3163, HR 1892 - lobbied House and Senate, CMS on proper implementation of the legislation. H.R.4724 - Medicare IVIG Access Enhancement Act, technical assistance
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · first_quarter · Medicare/Medicaid
114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act HR 3178, S. 1738, HR 3163, HR 1892 - lobbied House and Senate for temporary transitional home infusion clinical services reimbursement H.R.4724 - Medicare IVIG Access Enhancement Act, technical assistance
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · fourth_quarter · Medicare/Medicaid
114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act HR 3178, S. 1738, HR 3163 - lobbied House and Senate for temporary transitional home infusion clinical services reimbursement HR 3178, HR 3172, HR 3823 - IVIG Coverage Demonstration - Lobbied House and Senate for extension of demonstration. H.R. 4229, lobbied in support of the Protecting Home Oxygen & Medical Equipment Access Act
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · third_quarter · Medicare/Medicaid
114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act HR 3178, S. 1738, HR 3163 - lobbied House and Senate for temporary transitional home infusion clinical services reimbursement HR 3178, HR 3172, HR 3823 - IVIG Coverage Demonstration - Lobbied House and Senate for extension of demonstration. Various Medicare red tape issues submitted to Ways and Means Committee in response to their call for red tape reduction ideas, no legislation introduced.
Client expense: $101,295 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Trade (domestic/foreign)
NAFTA World Trade Organization (WTO) trade compliance Trade with: China, Cuba, Iraq, Japan, Korea, Mexico, Taiwan, Vietnam Crawford- Cuba Agricultural Exports Act, H.R. 525 Heitkamp/Boozman- Agricultural Export Expansion Act of 2015, S.275
Client expense: $80,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
| Democratic |
| MD |
| Bill Cassidy | Republican | LA |
| Christopher A. Coons | Democratic | DE |
| Chuck Grassley | Republican | IA |
| David Perdue | Republican | GA |
| Dianne Feinstein | Democratic | CA |
| James Lankford | Republican | OK |
| Jeanne Shaheen | Democratic | NH |
| Jerry Moran | Republican | KS |
| Kelly Ayotte | Republican | NH |
| Kirsten E. Gillibrand | Democratic | NY |
| Mark Kirk | Republican | IL |
| Mark R. Warner | Democratic | VA |
| Mazie K. Hirono | Democratic | HI |
| Michael F. Bennet | Democratic | CO |
| Pat Roberts | Republican | KS |
| Richard Blumenthal | Democratic | CT |
| Richard Burr | Republican | NC |
| Rob Portman | Republican | OH |
| Robert P. Casey, Jr. | Democratic | PA |
| Roger F. Wicker | Republican | MS |
| Sherrod Brown | Democratic | OH |
| Susan M. Collins | Republican | ME |
| Tammy Baldwin | Democratic | WI |
| Thad Cochran | Republican | MS |
2017 · second_quarter · Medicare/Medicaid
114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act 114th Congress HR 6 / HR 37 (21st Century Cures Act) - lobbied House and Senate to alter effective dates of Section 5012 and Section 5004 of the law. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries, Lobbied House and Senate for extension of demonstration.
Client expense: $139,005 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · first_quarter · Trade (domestic/foreign)
NAFTA World Trade Organization (WTO) trade compliance Trade with: China, Cuba, Iraq, Japan, Korea, Mexico, Taiwan, Vietnam Crawford- Cuba Agricultural Exports Act, H.R. 525 Heitkamp/Boozman- Agricultural Export Expansion Act of 2015, S.275
Client expense: $80,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2017 · first_quarter · Medicare/Medicaid
114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act 114th Congress HR 6 / HR 37 (21st Century Cures Act) - lobbied House and Senate to alter effective dates of Section 5012 and Section 5004 of the law. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries, Lobbied House and Senate for extension of demonstration.
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Health Issues
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · fourth_quarter · Medicare/Medicaid
RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · third_quarter · Health Issues
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · third_quarter · Medicare/Medicaid
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · second_quarter · Medicare/Medicaid
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · second_quarter · Health Issues
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · first_quarter · Medicare/Medicaid
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · first_quarter · Health Issues
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · fourth_quarter · Medicare/Medicaid
Patient access to disposable infusion pumps. Medicare Home Infusion Site of Care Act (S.275/H.R.605)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
S. 275-Medicare Home Infusion Site of Care Act of 2015, H.R. 2570-Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, H.R. 1611-Protecting Access to Rural Therapy Services (PARTS) Act, H.R. 34- 21st Century Cures Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Issues related to implementation of Section 1557 of ACA HR 793 - Ensuring Seniors Access to Local Pharmacies Act HR 2570-Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 HR 605-Medicare Home Infusion Site of Care Act S 275-Medicare Home Infusion Site of Care Act
Client expense: $2,080,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
H.R. 34, the 21st Century Cures Act H.R. 512, the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act S. 145, the Promise for Antibiotics and Therapeutics for Health Act S. 275, the Medicare Home Infusion Site of Care Act Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
S. 275, Medicare Home Infusion Site of Care Act of 2015; Medicare reimbursement for home infusion services, generally; H.R. 6, 21st Century Cures Act, and H.R. 34, 21st Century Cures Act, provisions related to home infusion and ASP.
Client expense: Not reported · Firm income: $20,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Client expense: $350,000 · Firm income: Not reported
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
PL 111-148 - The Patient Protection and Affordable Care Act, implementation, ESRD, clinical laboratory payment H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1470/S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 Part B demonstration H.R. 5122 - Part B demonstration H.R. 34 - 21st Century Cures Act ***, no specific bill(s), Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, MS, Infusion, oncology, CMMI S. 275/H.R. 609 - Home Infusion Site of Care Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Medicare/Medicaid
Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. S. 275 and H.R. 605 - Medicare Home Infusion Site of Care Act of 2015. H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 / HR 34 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program. Lobbied for inclusion of services payment under the legislation. Medicare Program; Part B Drug Payment Model - lobbied House and Senate regarding the effects of the Medicare Program; Part B Drug Payment Model demonstration project released on Friday, March 11, 2016 (81 FR 13229). MLN Learning Matters SE- 1609 and DME MAC Billing Guidance-Billing for External Infusion Pumps and Drugs When Treatment Was Initiated Somewhere Other Than the Beneficiary Home - Lobbied for delay in MLN Learning Matters and a moratorium on the Billing Guidance.
Client expense: $125,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Health Issues
Medicare Part B Drug Payment Model Proposal S. 275 / H.R. 605 - Medicare Home Infusion Site of Care Act H.R. 1600, Patients Access to Treatments Act 21st Century Cures Act Zika Virus / Public Health Preparedness
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
H.R. 34, The 21st Century Cures Act; S. 275 / H.R. 605, The Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration; H.R. 2028, Further Continuing and Security Assistance Appropriations Act of 2017.
Client expense: Not reported · Firm income: $52,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
S. 2425 - Patient Access and Medicare Protection Act H.R. 605/S. 275 - Medicare Home Infusion Site of Care Act H.R. 4273 - Medicare and Medicaid Improvements and Adjustments Act, ASP H.R. 5210/S. 2736 - Patient Access to Durable Medical Equipment Act H.R. 34 - 21st Century Cures Act **no specific bills; ASP, competitive bidding, Part B demonstration, MLN Learning Matters Billing Guidance H.R. 5122 - Part B demonstration
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R.605/S.275, Medicare Home Infusion Site of Care Act of 2015; P.L.114-255, 21st Century Cures Act; issues related to patient infusion therapy. Regulations related to Medical Device User Fee Amendments (MDUFA). Issues related to Medicare reimbursements for tracheotomy tubes. Issues related to inspection process of medical device facilities.
Client expense: $430,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Transportation Security Administration (TSA), U.S. Customs & Border Protection
2016 · fourth_quarter · Health Issues
Medicare Part B Drug Payment Model Proposal S. 275 & H.R. 605: Medicare Home Infusion Site of Care Act H.R. 1600: Patients Access to Treatments Act CURES Zika Virus/Public Health Preparedness
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment, oppose use of savings from home infusion payment reform for purposes other than creating a Medicare home infusion benefit; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6, now P.L.114-255) - support, but with serious concerns about the misalignment of implementation dates for two home infusion provisions - oppose implementation of Section 5004 (a) without aligning the start date of the new Medicare home infusion service benefit in Section 5012; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913)- support (with some concerns about pharmacy lock-in policy); submitted comments on Management Standards for Hazardous Waste Pharmaceuticals (EPA-HQ-RCRA-2007-0932); meeting with DEA on Controlled Substances Act (21 USC 802); proposed changes to regulation of Laboratory Developed Tests (FDA-2011-D-0360-Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests) - oppose; Comprehensive Addiction and Recovery Act of 2016 ((S.524), monitoring for pharmacy lock-in policy, which includes exemption for LTC) - support; Increasing Competition in Pharmaceuticals Act (S.2615/H.R.4784) - support; CREATES Act addressing REMS abuses (S.3056) - support; submitted comments in response to HRSA proposed rule establishing an Administrative Dispute Resolution (ADR) Process for the 340B Drug Purchasing Program (81 Fed. Reg. 53,381).
Client expense: $400,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
2016 · fourth_quarter · Medicare/Medicaid
Graduate Medical Education (GME) issues (including Resident Physician Shortage Reduction Act (H.R.2124/S.1148) - support); provided comments to Congress in response to Energy and Commerce Committee request for input on GME; amendments to the Medicare hospital re-admissions penalty program methodology (providing SES adjustments, fixing the formula flaw), H.R.1343/S.688 - support; proposals to amend the 2 midnight policy - support; hospital issues included in President Obama's FY 16 budget - oppose; hospital issues included in H.R.2, the Medicare Access and CHIP Re-authorization Act of 2015 - support; legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; Strengthening Medicare Advantage through Innovation and Transparency for Seniors (H.R.2570) - oppose; Medicare Inpatient Prospective Payment System FY 2016 proposed rule (CMS 1632-P) - detailed comment letter; legislation to improve the recovery audit contractor program (H.R.2156); Audit and Appeal Fairness, Integrity and Reforms in Medicare Act (AFIRM) - provided comments to the Senate Finance Committee; Ensuring Seniors Access to Local Pharmacies Act of 2015 (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Act (S.776) - support; CMS-4159-F2 - comments on daily dispensing fees; Medicare Independence at Home Medical Practice Demonstration Improvement Act of 2015 (P.L.114-39) - support; provided comments on the proposed Medicare outpatient prospective payment system rule (CMS-1633-P); Medicare IME Pool Act of 2015 (H.R.3292) - oppose; Strengthening DSH and Medicare through Subsidy Recapture and Payment Reform Act (H.R.3288) - oppose; Medicare Crosswalk Hospital Code Development Act (H.R. 3291) - oppose; sign-on letter to CMS urging it to reconsider negative update for CY 2016 (CMS-1633-P) - support; proposed Medicare and Medicaid cuts as offsets to pay for budget increases, raising the debt ceiling, etc. - oppose; site neutral hospital outpatient cuts and other hospital related provisions included in the Bipartisan Budget Act of 2015 (H.R. 1314) - oppose; legislative proposals (H.R. 5273)and Congressional letters to amend the Bipartisan Budget Acts site neutral hospital outpatient payment cut to grandfather sites under development as well as other legislative changes (support) - advocated for their inclusion in the Consolidated Appropriations Act of 2016 (Omnibus legislation/Senate amendment to H.R. 2029); provided comments to Congress regarding provisions in the Mental Health Reform Act of 2015 (S. 1945), that would reform how health care information for substance abuse patients is shared; met with HHS officials on Medicare and Medicaid issues of importance to the Commonwealth of Puerto Rico and Puerto Rican health care providers; submitted comments on Medicare and Medicaid Programs: Reform of Requirements for Long-Term Care Facilities (CMS-3260-P); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913) - support (with some concerns about pharmacy lock-in policy); hospital issues included in House FY 17 budget - oppose; hosptial issues included in President Obama's FY 17 budget proposal - oppose; provided comments in response to Energy and Commerce Committee request for input on hospital site-neutral issues; Medicaid provisions included in the Common Sense Savings Act of 2016 (H.R.4725) - oppose; provided comments to CMS and Congress regarding the Hospital Compare Star Ratings for hospitals - support for delay and fixing measures; The Fair Medicare Hospital Payments Act of 2016 (H.R. 4428) - oppose; provided comments to CMS on hospital site-neutral proposals - argued for flexibility in the anticipated OPPS proposed rule; provided comments to CMS on the FY 17 IPPS proposed rule (CMS-1655-P) with a focus on opposition to the proposed Medicare DSH policy and provided input to Capitol Hill and the Administration;submitted comments on Medicaid Program,Covered Outpatient Drugs (CMS-2345-FC); asked Congressional members to urge CMS to finalize its 2014 proposed guidance to Part D drug plans and PBMs regarding consistent reporting of Direct and Indirect Remuneration (DIR); Improving Transparency & Accuracy in Medicare Part D Spending (S.3308/H.R.5957) - support; testified at House Ways and Means Health Subcommittee hearing entitled "Incentivizing Quality Outcomes in Medicare Part A" in support of streamlining hospital measures and reporting; provided comments regarding the Medicare OPPS CY2017 proposed rule (81 FR 45603), in particular in opposition to implementation of site-neutral proposals; provided comments on Merit Based Incentive Payment System (MIPS)and Alternative Payment Models (APMs) under MACRA 2015 (81 FR 28161); discussions with CMS regarding priority categories for redistribution of Medicare-funded residency slots; discussions with CMS to encourage consistency in hospital surveys; submitted comments on the Part B Drug Payment Model proposed rule (CMS-1670-P) - serious concerns; submitted comments on the SNF PPS proposed rule (CMS-1645-P) - serious concerns; Texas proposed Medicaid State Plan Amendment (15-005) in response to the CMS Covered Outpatient Drug Rule (CMS-2345-FC) - concerns; submitted comments to CMS about its proposal to expand testing of mandatory, risk-based bundled payments for acute episodes of care - oppose; 21st Century Cures Act (H.R. 34, now P.L.114-255) provisions that apply to site neutral, readmissions, and other hospital reimbursement issue - support.
Client expense: $400,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
2016 · fourth_quarter · Medicare/Medicaid
H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs. H.R.34, 21st Century Cures Act (P.L.114-255); S.275, Medicare Home Infusion Site of Care Act of 2015; Medicare issues including reimbursement and home infusion therapy in Part B DME (durable medical equipment).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · fourth_quarter · Medicare/Medicaid
RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · third_quarter · Medicare/Medicaid
H.R. 546: ACE KIDS ACT OF 2015; PROVISIONS RELATED TO MEDICAID ACCESS TO THERAPY H.R. 605: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO MEDICARE ACCESS TO THERAPY S 298: ACE KIDS ACT OF 2015; PROVISIONS RELATED TO MEDICAID ACCESS TO THERAPY S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO MEDICARE ACCESS TO THERAPY
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
HR 546: Advancing Care for Exceptional (ACE) Kids Act of 2015; all provisions of the bill HR 605: Medicare Home Infusion Site of Care Act of 2015; all provisions of the bill S. 275: Medicare Home Infusion Site of Care Act of 2015; all provisions of the bill
Client expense: $60,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
HR: 6: 21st Century Cures Act; all provisions of the bill HR: 546: Advancing Care for Exceptional (ACE) Kids Act of 2015; all provisions of the bill HR: 605: Medicare Home Infusion Site of Care Act of 2015; all provisions of the bill HR: 4909: National Defense Authorization Act for Fiscal Year 2017; provisions related to Cystic Fibrosis care exemption HR: 5054: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; provisions related to Food and Drug Administration funding HR: 5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act; provisions related to National Institutes of Health funding and Food and Drug Administration funding HR: 5926: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; provisions related to National Institutes of Health funding S. 185: Promised for Antibiotic and Therapeutics for Health (PATH) Act; all provisions of the bill S. 275: Medicare Home Infusion Site of Care Act of 2015; all provisions of the bill S. 298: Advancing Care for Exceptional (ACE) Kids Act of 2015; all provisions of the bill S. 1878: Advancing Hope Act of 2016; all provisions of the bill S. 2014: Next Generation Researchers Act; all provisions of the bill S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016; all provisions of the bill S. 2511: Improving Health Information Technology Act; all provisions of the bill S. 2700: FDA and NIH Workforce Authorities Modernization Act; all provisions of the bill S. 2713: Advancing Precision Medicine Act of 2016; all provisions of the bill S. 2943: National Defense Authorization Act for Fiscal Year 2017; provisions related to Cystic Fibrosis care exemption S. 2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; provisions related to Food and Drug Administration funding S. 3040: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017; provisions related to National Institutes of Health funding General Discussions related to National Institutes of Health and Food and Drug Administration funding Discussions related to Prescription Drug User Fee Act VI; all provisions of the proposal
Client expense: $60,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Patient access to disposable infusion pumps. Medicare Home Infusion Site of Care Act (S.275/H.R.605)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
HR 793 - Ensuring Seniors Access to Local Pharmacies Act HR 4062 - Protecting Seniors Access to Proper Care Act of 2015 HR 2570-Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 HR 605-Medicare Home Infusion Site of Care Act S 275-Medicare Home Infusion Site of Care Act H.R. 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $1,320,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
Medicare Part B Drug Payment Model Proposal S. 275 / H.R. 605 - Medicare Home Infusion Site of Care Act H.R. 1600, Patients Access to Treatments Act
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Client expense: $570,000 · Firm income: Not reported
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medical/Disease Research/Clinical Labs
H.R.605/S.275, Medicare Home Infusion Site of Care Act of 2015; H.R.6, 21st Century Cures Act; issues related to patient infusion therapy. Regulations related to Medical Device User Fee Amendments (MDUFA). Issues related to Medicare reimbursements for tracheotomy tubes. Issues related to inspection process of medical device facilities.
Client expense: $600,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Guard, SENATE, Transportation Security Administration (TSA), U.S. Customs & Border Protection
2016 · third_quarter · Medicare/Medicaid
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, The Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: Not reported · Firm income: $52,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
S. 275, Medicare Home Infusion Site of Care Act of 2015; Medicare reimbursement for home infusion services, generally
Client expense: Not reported · Firm income: $20,000
Government targets: Executive Office of the President (EOP), SENATE
2016 · third_quarter · Health Issues
H.R. 6, the 21st Century Cures Act H.R. 512, the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act S. 145, the Promise for Antibiotics and Therapeutics for Health Act S. 275, the Medicare Home Infusion Site of Care Act Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program. Medicare Program; Part B Drug Payment Model - lobbied House and Senate regarding the effects of the Medicare Program; Part B Drug Payment Model demonstration project released on Friday, March 11, 2016 (81 FR 13229). MLN Learning Matters SE- 1609 and DME MAC Billing Guidance-Billing for External Infusion Pumps and Drugs When Treatment Was Initiated Somewhere Other Than the Beneficiary Home - Lobbied for delay in MLN Learning Matters and a moratorium on the Billing Guidance.
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Medicare/Medicaid
S. 2425 - Patient Access and Medicare Protection Act H.R. 605/S. 275 - Medicare Home Infusion Site of Care Act H.R. 4273 - Medicare and Medicaid Improvements and Adjustments Act, ASP H.R. 5210/S. 2736 - Patient Access to Durable Medical Equipment Act **no specific bills; ASP, competitive bidding, Part B demonstration, MLN Learning Matters Billing Guidance H.R. 5122 - Part B demonstration
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE